MAIA Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Participate in the 36th Annual ROTH Conference.

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at AACR Annual Meeting.

MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients.

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders.

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer.

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds.

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

MAIA Soars 20% on Interim Results From Lung Cancer Study

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024.

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

Lead asset THIO has a unique telomere-targeting mechanism and has reported impressive preliminary results in NSCLC. THIO's 90%+ disease control rate in second- and third-line NSCLC is an improvement over current standard of care. Plans to pursue accelerated approval in NSCLC in 2025 and has the potential to become a new standard of care.

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer.

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (MAIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering.

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths annually.

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $4 Million Registered Direct Offering.

MAIA Biotechnology Announces $4 Million Registered Direct Offering

CHICAGO--(BUSINESS WIRE)--FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma.

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO.

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments. CHICAGO, IL / ACCESSWIRE / October 31, 2023 / MAIA Biotechnology Inc. (NYSE:MAIA) is focused on the development and commercialization of drugs that improve and extend the lives of people with cancer.

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO.

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces 100% Disease Control in 2nd Line NSCLC Demonstrating Impressive Positive Preliminary Efficacy for Ongoing Phase 2 Trial.

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 2023.

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

CHICAGO, IL / ACCESSWIRE / October 17, 2023 / Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. Radiotherapy, the current standard of care, has limitations, including short-lived responses that last about six to nine months on average.

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at International Biochemistry Congress 2023.

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society's International Biochemistry Congress 2023

News for MAIA Biotechnology Inc Stock (MAIA)